Good MorningEquity markets rebounded for another day on Thursday as traders gear up for the Q2 earnings reporting season. The peak of the season begins next week with reports from the big banks and the news is expected to be dismal. At best, the banks will report tepid growth with a high likelihood of earnings contraction. The contraction will be due in large part to increased credit reserves in the face of an oncoming recession, the question is how big will the build-up be?
Friday action will be dominated by the NFP report which is expected to show a slowdown in job gains. The question here regards wages and how fast earnings are growing? While good for the average new job taker the persistent increase in labor costs is bad news for businesses and consumers. Next week, investors will have a wave of economic data to wade through including the CPI for June and Retail Sales. Featured: The case for trading fewer setups, not more (Ad) 
|
Technology | | Data infrastructure networking solutions and licenses provider Credo Technology (NASDAQ: CRDO) stock is only down a merciful (-3%) for the year. It’s worth noting that the fabless semiconductor company only recently IPO’ed in January of 2022 but shares have been resilient due to its stro... Read the Full Story |
|
From Our Partners | | Oracle runs 15,000 stocks through the same filter every single day, scanning for precise setups before the opening bell - no emotion, no guesswork.
Tim Bohen, Lead Trainer at StocksToTrade, is walking through this week's flagged setups and showing exactly how the scanner works in a live training right now. | | Watch the scanner in action and join the live training now |
|
Markets | |
Insider Buying Picks Up For These Stocks
While insider buying is no guarantee for higher share prices it is certainly an indication of optimism and value in a stock. This is why we like to scope out the insider-buying data, it’s a valuable source for trading ideas. What we found today is a... Read the Full Story |
|
Markets | |
Volatility On The Rise For Roblox Shares
We recently saw some coverage of Roblox (NASDAQ: RBLX) that led us to believe it could be a great play for the 2nd half. The story suggested a recent pop in share prices was due to increased retail chatter that may lead to a short-squeeze, it even suggeste... Read the Full Story |
|
From Our Partners | | Every morning before the market opens, a scanner called Oracle runs through 15,000 stocks and scores the setups — so there's already a plan in place by 6:15 a.m.
Lead Trainer Tim Bohen of StocksToTrade is walking through exactly how Oracle works and how regular traders are using it in a training running right now. | | Watch the Oracle training now and see how the scanner works |
|
Technology | | Shares of semiconductor stock Micron (NASDAQ: MU) have been trading down quite aggressively since the end of last year. Despite a bit of a bounce this week (more on that later) they’ve still fallen as much as 45% from the all-time highs they printed back in November. But with the halfway point... Read the Full Story |
|
Technology | |
Samsung Lifts Chip Stocks On Cloud-Driven Demand
Samsung (OTC: SSNLF) reported a mixed quarter but details within the report are lifting the chip sector. While the news may have sparked a near-term bottom we’re not sure it will stick. The company reported a stronger-than-expected demand fo... Read the Full Story |
|
From Our Partners | | The U.S. government has taken roughly a 10% stake in Intel, negotiated a 15% cut of Nvidia and AMD chip sales to China, and reportedly received a 5% ownership offer - worth around $40 billion - from the most valuable AI company on earth.
Porter Stansberry calls it the New U.S.A.I. - a state-backed arrangement where Washington and a handful of tech giants are fused at the balance sheet. A small number of companies get pulled inside. Everyone else gets frozen out, including names sitting in your index fund right now. | | Watch the documentary to see which companies are on the right side |
|
Consumer Staples | |
Helen Of Troy Beats Consensus But Guides Lower
Helen of Troy (NASDAQ: HELE) had a strong quarter in Q2 but the results and guidance are what we fear most about the Q2 earnings reporting cycle. Not only were the results boosted by businesses and consumers trying to front-run inflation but the gui... Read the Full Story |
|
Energy | |
When it comes to investing styles, growth, and value are the OG’s. The advent of factor investing has added many more to the mix but growth and value remain popular ways for institutions and individuals to evaluate stocks.
Growth can be defined in any number of ways that suit the investor's... Read the Full Story |
|
Industrials | |
Capitulation In Kornit Digital Market Could Lead To A Rebound
Kornit (NASDAQ: KRNT) appeared to be perfectly set up for the times but the times changed too quickly and that story is played. The company manufactures, markets, and services a range of digital printing applications for the textile a... Read the Full Story |
|
Medical | | Healthcare ecosystem management platform developer Phreesia (NYSE: PHR) stock is sunk (-40%) on the year. The Company caters to small to medium sized physician offices with a cloud-based software as a service (SaaS) platform that optimizes workflow and operation efficiency. It’s automated tool... Read the Full Story |
|
Markets | | Luxury fashion brand retailer Capri Holdings Limited (NASDAQ: CPRI) stock has fallen (-37%) for the year. With high end premium brands like Versace, Michael Kors, and Jimmy Choo, Capri Holdings caters to the higher-income demographic. It’s high-end consumers are helping drive double-digit sal... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
